<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517852</url>
  </required_header>
  <id_info>
    <org_study_id>17-009823</org_study_id>
    <nct_id>NCT03517852</nct_id>
  </id_info>
  <brief_title>Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)</brief_title>
  <official_title>Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the tumor-associated vasculature of patients with peritoneal
      carcinomatosis, or cancer that spreads along the inner abdominal lining. The investigators
      will use a technology known as intravital microscopy (IVM) in order to visualize in real-time
      the tumor-associated vessels of peritoneal disease. The IVM observations may determine if an
      individual patient's tumor vessels would be amenable to receiving systemic therapy, based on
      the functionality of the vessels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective(s): To determine the feasibility and clinical utility of performing HIVM in
      patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive
      surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).

      Secondary objective(s):

        1. Compare the microscopic observation of the tumor-associated vessels with normal tissue
           (peritoneal surface) in each individual subject.

        2. Correlate the microscopic observations of the tumor-associated vessels with pathologic
           grade of tumor implants.

        3. Correlate the microscopic observation of the microvasculature with tumor-specific and
           overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label, non-randomized, single center, study of IVM observation in conjunction with fluorescein and ICG in subjects with peritoneal carcinomatosis undergoing CRS-HIPEC.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor vessel identification (# tumor vessels visualized per high power field)</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Identify and measure vessels associated with peritoneal tumor implants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor vessel density (# tumor vessels per square cm area observed)</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Determine vessel density per 10x field</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake)</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Visualize vital dyes within the vessels [fluorescein and indocyanine green (ICG)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor blood flow (velocity, mm/sec)</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Calculate the blood flow velocity of the vessels and tissue penetration of fluorescent dyes as markers of vessel permeability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative comparison of the microvasculature of peritoneal carcinomatosis with normal tissue (peritoneum)</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>The investigators will compare the microvasculature of peritoneal carcinomatosis with normal tissue (peritoneum) in each individual subject using vessel characteristics (diameters, vessel density, detection of intravital dye and flow rates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative correlation of the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).</measure>
    <time_frame>5-7 days</time_frame>
    <description>The investigators will determine if there is a correlation between the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will determine if there is a correlation between the microscopic observation of the tumor microvasculature tumor-specific and overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Human Intravital Microscopy</intervention_name>
    <description>Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years of age.

          2. Have an ECOG Performance Status of ≤ 2. Refer to Appendix C.

          3. Have measurable disease in the peritoneum by direct visualization (visible lesion
             typically &gt; 0.5 cm in maximal diameter).

          4. Carcinomatosis that meets indications for CRS-HIPEC.

          5. Subject must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure.

          6. A negative skin-prick test to fluorescein.

        Exclusion Criteria:

          1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations.

          2. Renal dysfunction as defined as a GFR &lt; 45.

          3. Liver dysfunction as defined by Child-Pugh score &gt; 5, or LFT's 1.5x above normal
             range.

          4. Any known allergy or prior reaction to fluorescein or ICG or a positive skin prick
             test to fluorescein.

          5. Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy
             test.

          6. Unwilling or unable to follow protocol requirements.

          7. Any condition which in the Investigators' opinion deems the patient unsuitable (e.g.,
             abnormal EKG).

          8. Any condition that excludes CRS-HIPEC as the standard of care for the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel M Gabriel, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel M Gabriel, M.D., Ph.D.</last_name>
    <phone>904-953-2523</phone>
    <email>gabriel.emmanuel@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael B Wallace, M.D.</last_name>
    <phone>904-953-2221</phone>
    <email>wallace.michael@mayo.edu</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011 Oct;121(10):3846-59. doi: 10.1172/JCI44952. Epub 2011 Sep 19.</citation>
    <PMID>21926464</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016 Feb 17;7:10684. doi: 10.1038/ncomms10684.</citation>
    <PMID>26883450</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Review.</citation>
    <PMID>20490982</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer. 2009 Mar 24;100(6):865-9. doi: 10.1038/sj.bjc.6604929. Epub 2009 Feb 24. Review.</citation>
    <PMID>19240721</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.</citation>
    <PMID>20061178</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr;17(3):206-25. doi: 10.1111/j.1549-8719.2010.00029.x. Review.</citation>
    <PMID>20374484</PMID>
  </results_reference>
  <results_reference>
    <citation>Skitzki JJ, Chen Q, Wang WC, Evans SS. Primary immune surveillance: some like it hot. J Mol Med (Berl). 2007 Dec;85(12):1361-7. Epub 2007 Aug 18. Review.</citation>
    <PMID>17704903</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002 Apr;2(4):266-76. Review.</citation>
    <PMID>12001988</PMID>
  </results_reference>
  <results_reference>
    <citation>Murooka TT, Mempel TR. Multiphoton intravital microscopy to study lymphocyte motility in lymph nodes. Methods Mol Biol. 2012;757:247-57. doi: 10.1007/978-1-61779-166-6_16.</citation>
    <PMID>21909917</PMID>
  </results_reference>
  <results_reference>
    <citation>Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol. 2013 Mar;Chapter 19:Unit19.7. doi: 10.1002/0471143030.cb1907s58.</citation>
    <PMID>23456602</PMID>
  </results_reference>
  <results_reference>
    <citation>McLaughlin RA, Scolaro L, Robbins P, Hamza S, Saunders C, Sampson DD. Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer. Cancer Res. 2010 Apr 1;70(7):2579-84. doi: 10.1158/0008-5472.CAN-09-4062. Epub 2010 Mar 16.</citation>
    <PMID>20233873</PMID>
  </results_reference>
  <results_reference>
    <citation>Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, Condeelis JS. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital. 2013 Apr 1;2(2):e25294.</citation>
    <PMID>25013744</PMID>
  </results_reference>
  <results_reference>
    <citation>Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.</citation>
    <PMID>22162570</PMID>
  </results_reference>
  <results_reference>
    <citation>Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010 Dec 15;116(24):5608-18. doi: 10.1002/cncr.25356. Epub 2010 Aug 24.</citation>
    <PMID>20737573</PMID>
  </results_reference>
  <results_reference>
    <citation>Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1;28(1):63-8. doi: 10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Apr 1;28(10):1808.</citation>
    <PMID>19917863</PMID>
  </results_reference>
  <results_reference>
    <citation>Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010 Sep;17(9):2370-7. doi: 10.1245/s10434-010-1039-7. Epub 2010 Mar 25.</citation>
    <PMID>20336386</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalogeromitros DC, Makris MP, Aggelides XS, Mellios AI, Giannoula FC, Sideri KA, Rouvas AA, Theodossiadis PG. Allergy skin testing in predicting adverse reactions to fluorescein: a prospective clinical study. Acta Ophthalmol. 2011 Aug;89(5):480-3. doi: 10.1111/j.1755-3768.2009.01722.x. Epub 2009 Nov 10.</citation>
    <PMID>19906081</PMID>
  </results_reference>
  <results_reference>
    <citation>Jaffer FA. Intravital fluorescence microscopic molecular imaging of atherosclerosis. Methods Mol Biol. 2011;680:131-40. doi: 10.1007/978-1-60761-901-7_9.</citation>
    <PMID>21153378</PMID>
  </results_reference>
  <results_reference>
    <citation>Munn LL, Padera TP. Imaging the lymphatic system. Microvasc Res. 2014 Nov;96:55-63. doi: 10.1016/j.mvr.2014.06.006. Epub 2014 Jun 21. Review.</citation>
    <PMID>24956510</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology. 1986 Dec;93(12):1617-20.</citation>
    <PMID>3808620</PMID>
  </results_reference>
  <results_reference>
    <citation>Bloom JN, Herman DC, Elin RJ, Sliva CA, Ruddel ME, Nussenblatt RB, Palestine AG. Intravenous fluorescein interference with clinical laboratory tests. Am J Ophthalmol. 1989 Oct 15;108(4):375-9.</citation>
    <PMID>2801858</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Emmanuel M. Gabriel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

